VARIAN PHARMED

Leaflet (front)	Marcovar® 0.5% heavy Bupivacaine
Size	170 x 163 (mm)
Date	1402.01.22

Colors:
- PANTONE 293 C
- Black

163 mm

170 mm

Marcovar® 0.5%

5 mg/ml

VARIAN PHARMED



Bupivacaine

10 x 4ml injection ampoules

For injection only

Read the contents of this guide carefully before using the medicine

This product is a specialized medication prescribed for your current condition.
Therefore, avoid using it in the future and in similar conditions without consulting your doctor, and refrain from recommending it to others with symptoms similar to yours.

For more information about this medication, consult your treating physician or pharmacist, or visit www.varianpharmed.com.
Dosage Form Bupivacaine, manufactured by Varian Pharmed, is available in ampoules containing 20 milligrams in 4 milliliters, packaged in boxes of 10, along with a user guide.

Indications Bupivacaine is a local anesthetic from the amino amide family with a rapid onset but a long duration of action.
Additionally, the speed of onset and duration of the drug's effect increase with the addition of a vasoconstrictor (such as epinephrine).

This drug is used for local anesthesia with peripheral nerve block, sympathetic, epidural lumbar, etc.

Dosage and Administration The treatment regimen, dosage, and treatment duration with this product are determined by the treating physician.
The amount of bupivacaine used depends on the site of injection and the method of use, as well as the patient's condition, which may vary. However, the usual dose of this drug is as follows
Recommended dose for adults and children over 12 years old Lower limb surgeries including hip surgery:

2 to 4 milliliters (10 to 20 milligrams) Lower abdominal surgery (including cesarean section): 2 to 4 milliliters (10 to 20 milligrams)

Urological surgery: 1.5 to 3 milliliters (7.5 to 15 milligrams) Recommended dose for infants and children weighing less than 40 kilograms

Weight less than 5 kilograms: 0.4 to 0.5 milligrams per kilogram of body weight
Weight between 5 and 15 kilograms: 0.3 to 0.4 milligrams per kilogram of body weight
Weight between 15 and 40 kilograms: 0.25 to 0.3 milligrams per kilogram of body weight.

VARIAN PHARMED

Leaflet (front)	Marcovar® 0.5% heavy Bupivacaine
Size	170 x 163 (mm)
Date	1402.01.22

Colors:
- PANTONE 293 C
- Black

163 mm

170 mm

Maximum dose:

There is no evidence of using more than 20 milligrams (4 milliliters).

Warnings and Precautions:

The drug dose should be reduced in elderly individuals, children, debilitated patients, and in patients with heart or liver diseases.

This drug should be administered by trained healthcare personnel in facilities equipped with oxygen, resuscitation drugs, and cardiac resuscitation equipment.
Do not mix this drug with other local anesthetics as there is insufficient information on the clinical use of its mixture with other drugs.

Vital signs, cardiovascular and respiratory, as well as the patient's consciousness status, should be carefully monitored after each local anesthesia injection (including bupivacaine).

Caution should be exercised in administering spinal anesthesia in patients with cardiac block, central nervous system disorders, hematological disorders, patients receiving anticoagulant drugs, blood pressure reduction or elevation, etc.
Hypotension may occur in hypovolemic patients during spinal anesthesia.
Like other local anesthetics, bupivacaine may cause systemic toxicity, including central nervous system, cardiovascular, and respiratory function impairment, and may ultimately lead to coma and respiratory arrest, especially when inadvertently injected intravenously.

Bupivacaine may cause drowsiness and decreased alertness, so driving and operating machinery requiring full alertness should be avoided during treatment.
Low doses of bupivacaine for local anesthesia in the head and neck area may lead to systemic toxicity.

Infants may be at increased risk of bupivacaine toxicity due to decreased protein binding, increased volume of distribution, decreased metabolism, and increased drug half-life.

Patients receiving anti-arrhythmic drugs should be closely monitored and ECG checked due to cardiac side effects. Dose Adjustment in Liver Disorders: If the patient has moderate to severe liver impairment, the drug dose should be reduced, and increased monitoring for bupivacaine toxicity is recommended. Pregnancy and Dose Adjustment in Renal Disorders: Bupivacaine is primarily excreted through the kidneys; therefore, the risk of toxicity is higher in patients with renal impairment, and dose adjustment is recommended in patients with renal problems.

Contraindications:

Bupivacaine or any type of local anesthetic from the amide group (ropivacaine, mepivacaine, lidocaine), or even other compounds in the Marcaine should not be used in patients with known hypersensitivity.
Bupivacaine solutions containing preservatives should not be used for epidural, caudal, and spinal anesthesia.

Manufactured by: Varian Pharmed, Tehran-iran